MaxCyte preliminary Q3 core revenue ~$8.1M, up 26% YoY; raises FY2026 revenue guidance to ~$34M

MAXCYTE, INC.

Q3 2026 preliminary core business revenue ~$8.1M, up 26% YoY; SPL Program-related revenue over $1.0M, including a $1.0M milestone received in Q3.
FY2026 revenue guidance raised to ~$34M from prior $30M-$32M: core business ~$28M (prior $25M-$27M) and SPL Program ~$6M (prior ~$5M).
SPL guidance includes ~$4M of milestone payments and ~$2M of commercial royalties; this was MaxCyte's second SPL milestone of 2026.
CEO Maher Masoud cites accelerated instrument purchasing from a large customer pulled forward from Q4; core business up ~15% YoY in H2 2026.
Royalty revenue and full results due Nov 10, 2026; two SPL-partner pivotal trials have potential approval as early as next year.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.